ADCT Stock — ADC Therapeutics SA Common Shares: Cash, EV, Pipeline

Share price

$1.05

Market cap

$134.1M

Cash

$219.1M

Enterprise value

-$85.0M

Balance sheet

Cash	$219.1M
Debt	$0.0M
Net cash	$219.1M
Enterprise value	-$85.0M
Basic shares	127.4M shares
Fully diluted shares	187.2M shares
Fully diluted market cap	$196.5M
Cash per share	$1.72

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ADCT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 12 - Jun 23	Loncastuximab Tesirine	Phase 1	B-Cell Non-Hodgkin Lymphoma; Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ZYNLONTA

Approved · Active Modality: CD19-directed antibody-drug conjugate

Aliases loncastuximab tesirine-lpyl

Target CD19

Partnerships Sobi (ex-US commercialization rights, excluding Greater China, Singapore, and Japan)

Indications

relapsed/refractory diffuse large B-cell lymphoma, third-line plus (Stage not disclosed)
earlier-line diffuse large B-cell lymphoma (LOTIS-5, Phase 3) (Stage not disclosed)
follicular lymphoma (Phase 2 investigator-initiated) (Stage not disclosed)
marginal zone lymphoma (Phase 2 investigator-initiated) (Stage not disclosed)

Catalysts

— None
— None
— None

Status note Approved for 3L+ R/R DLBCL. LOTIS-5 regulatory path under reassessment after FDA benefit-risk concerns.

PSMA-targeting ADC (unnamed)

Preclinical · Active Modality: antibody-drug conjugate

Target PSMA

Indications

not disclosed (Stage not disclosed)

Status note IND-enabling activities completed. Remaining solid-tumor preclinical programs were discontinued in the June 2025 restructuring.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Loncastuximab Tesirine
Lead indication	Relapsed Diffuse Large B-Cell Lymphoma
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04384484	Phase 3	Active, not recruiting	Sponsor	ADC Therapeutics S.A.	—	Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma	—
NCT04970901	Phase 1	Active, not recruiting	Sponsor	ADC Therapeutics S.A.	—	B-Cell Non-Hodgkin Lymphoma; Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for ADC Therapeutics S.A. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	0	-1,318,026	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ADCT — ADC Therapeutics SA Common Shares